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Evaluation of a PACAP peptide analogue labeled with 68Ga using two different chelating 
agents. 
Pardeep Kumar1, Sushil Tripathi1, Chang-Po Chen2, Neil Mehta1, Bishnuhari paudyal1,  Eric 
Wickstrom3,4, Mathew L. Thakur*1,4,5. 
 
ABSTRACT 
Objective: The authors have conjugated chelating agents (DOTA and NODAGA) with a peptide 
(PACAP analogue) which has a high affinity for VPAC1 receptors expressed on cancer cells. In 
order to determine a suitable chelating agent for labeling with 68Ga, we have compared the 
labeling kinetics and stability of these peptide conjugates.  
Methods: For labeling, 68GaCl3 was eluted in 0.1 M HCl from a [
68Ge-68Ga] generator. The 
influences of peptide concentration, pH and temperature on the radiolabeling efficiency were 
studied. The stability was evaluated in saline, human serum, DTPA, Transferrin and metallic 
ions (FeCl3, CaCl2 and ZnCl2). Cell binding assay was performed using human breast cancer 
cells (T47D). Tissue biodistribution was studied in normal athymic nude mice.  
Results: Optimal radiolabeling (> 95.0%) of the DOTA-peptide conjugates required higher 
(50°C–90ºC) temperature and 10 min incubation at pH 2–5. The NODAGA-peptide conjugate 
needed incubation only at 25°C for 10 min. Both radio-complexes were stable in saline, serum as 
well as against transchelation and transmetallation. Cell binding at 37°C for 15 min incubation 
with 68Ga-NODAGA-peptide was 34.0% as compared to 24.5% for 68Ga-DOTA-peptide. Tissue 
biodistribution at 1 hr post-injection of both 68Ga labeled peptide conjugates showed clearance 
through the kidneys.  
Conclusions: NODAGA-peptide showed more convenient radiolabeling features than that of 
DOTA-peptide.  
Key words: Breast cancer, Prostate Cancer, chelating agent, peptides, radiopharmaceuticals. 
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Introduction 
 
Positron emission tomography (PET) has become a prominent imaging modality in the field of 
oncology.1 PET has several technical advantages over the single photon emission computed 
tomography (SPECT) like attenuation correction, and higher spatial resolution.2-3 Small 
molecules such as sugars, amino acids, nucleic acids, or receptor-binding ligands are labeled 
with positron-emitting radionuclides for PET imaging to study in vivo visualization of 
physiological processes on a molecular level.4-7 There are several positron emitting radionuclides 
like fluorine-18 [18F] (t1/2 ≈ 110 min), copper-64 [
64Cu] (t1/2 ≈12.7 hr), carbon-11 [11C] (t1/2 ≈ 20 
min), and oxygen-15 [15O] (t1/2 ≈ 2 min). However, their production requires in-house cyclotron, 
not available at every academic institution and hospital.  
 
In recent years, Gallium-68 [68Ga] - a positron emitting radionuclide conveniently available in 
the form of Germanium-68 (t1/2 ≈ 270 days)-Gallium-68 (t1/2 ≈ 68 min) [68Ge     68Ga] generator 
has drawn considerable attention for oncologic diagnostic applications. The short physical half-
life of 68Ga  induces low radiation burden on patients and makes it an ideal radionuclide for 
diagnostic use.8-10 The labeling of biomolecules with 68Ga is achieved by using bi-functional 
chelators (BFC) such as DTPA (diethylene triamine pentaacetic acid), DOTA (1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclononane-1,4,7-triacetic 
acid), or NODAGA (1,4,7-triazacyclononane-1-glutamic acid-4,7-diacetic acid). BFCs differ 
from each other in their physio-chemical properties which can influence radiolabeling kinetics. 
They can also influence overall charge of the complex, biodistribution and more importantly 
uptake in the tumor site.11-13 
 
In recent years, there has been increasing interest in the receptor targeted scintigraphy in which 
peptides have emerged as promising biomolecules.14 Their properties such as fast clearance, 
rapid tissue penetration, low antigenicity, and relatively easy synthesis have added to their 
applicability.15 In past few years, our laboratory has designed, synthesized and radiolabeled 
peptide conjugates which have high affinity for VPAC-1 receptors, over-expressed in many 
malignant tumors including those of the breast and prostate.16-20 The peptides are analogues of 
Pituitary adenylate cyclase-activating peptide (PACAP) - a 27 amino acid peptide and vasoactive 
intestinal peptide (VIP)- 28 amino acid. Both have similar biochemical properties and bind to 
VPAC1 receptors expressed in high density on the surface of certain cancers such as of the 
breast, prostate and urinary bladder (100%), colon (96%), pancreas (65%), lung (58%), stomach 
(54%), and liver (49%).21-24 
 
The present study was aimed to investigate the influence of these two BFC agents on the PACAP 
analogue, which differs in terms of their radiolabeling kinetics, biological activity and stability of 
the resultant product.  
 
 Methods and materials 
 
Reagents 
 
Fmoc amino acid, solvents and reagents for peptide chelator synthesis, was purchased 
from Fluka Chemicals (St. Louis, MO). The BFC DOTA was purchased from 
Macrocyclics (Dallas, TX) and NODAGA was purchased from Chematech (Dijon, 
France). Sodium acetate, diethylenetriamine pentaacetic acid (DTPA), calcium chloride 
(CaCl2), zinc chloride (ZnCl2), Ferric chloride (FeCl3), hydrochloric acid solutions were 
purchased from Fisher Scientific, Inc. (Waltham, MA). Transferrin was purchased from 
Sigma-Aldrich (St. Louis, MO). A 370MBq [68Ge-68Ga] generator was purchased from 
Eckert and Zeigler (Berlin, Germany). Sodium chloride solution (0.9%) was prepared in 
this laboratory using deionized water. Human serum was prepared from whole blood 
drawn from a volunteer. All chemicals were used without further purification. 
 
Instruments 
 
Peptide was purified using a preparative column on high-pressure liquid chromatography 
(HPLC) system (Shimadzu Corporation, Kyoto, Japan) equipped with gradient pumps 
and UV/VIS detector, a NaI(Tl) radioactivity monitor, and a rate meter. The reverse 
phase C18 microbound column (4.6 mm × 250 mm) served as the stationary phase, and 
two solvents: 0.1% Trifluoroacetic acid (TFA) in H2O and 0.1% TFA in acetonitrile as 
mobile phase. The gradient was such that 10% CH3CN in aqueous 0.1% CF3COOH to 
100% CH3CN in 0.1% CF3COOH at a flow rate of 1 mL/min over 28 min at 22°C. For 
thin layer chromatography (TLC), pre-coated aluminum sheets with silica gel were 
purchased from Merck (Kenilworth, NJ) and radioactivity was measured on Perkin Elmer 
2480 wizard2 automatic gamma counter (Waltham, MA). The pH of the solutions was 
measured using either a pH meter (Sartorius, Gottingen, Germany) or pH strips (Fisher 
scientific Inc.) 
  
Synthesis of peptide conjugate 
 
Briefly, the PACAP analogue with C-terminal NODAGA/DOTA chelators was 
synthesized on a Wang resin using an ABI 341A peptide synthesizer (Applied 
Biosystems, Foster City, CA). Fmoc-Lys (ivDde) was first introduced at the C terminus 
of the peptide, followed by 4-aminobutyric acid (y-Aba). The 27-amino-acid-long 
PACAP sequence was then assembled by standard Fmoc coupling with the final histidyl 
residue, being a t-Boc–protected His(Trt) derivative. The capping t-Boc function was 
necessary to ensure that the N-terminal amino group remained protected during 
subsequent deprotection and coupling cycles performed at the c amino group of the C-
terminal lysine. The ivDde group at the C-terminal lysine was then selectively removed 
with 2% hydrazine, followed by coupling with DOTA or NODAGA. The peptide was 
cleaved from the resin using TFA/water/ phenol/thioanisole/ethanedithiol (82.5:5:5:5:2.5) 
and precipitated with diethyl ether. The crude peptide was purified to homogeneity by 
reversed phase HPLC using a preparative column. The peptide was characterized by 
matrix-assisted laser desorption/ionization- time of flight (MALDI-TOF) mass 
spectrometry. 
 
Radiolabeling 
 
For radiolabeling, 300 µL (14.5 – 18.5 MBq) of 68GaCl3 was added in a clean glass test 
tube to which were added varying amounts of acetate buffer to study the influence of pH 
(1.0 – 6.0) and varying amount of a 4 mg/mL peptide-chelators water solution (1-20 µg). 
The mixture was heated at predetermined temperatures (25, 50, 70 and 90 °C) for pre 
chosen time periods (10, 15, 20 and 30 min) to study the kinetics of the radiolabeling 
reactions with respect to temperature and time. The radiolabeling was evaluated by 
Radio-HPLC.  
 
Preparation of free 68GaCl3, 
68Ga-hydrolyzed, 68Ga-DTPA and 68Ga-Tf as reference 
standard 
 
To identify HPLC peaks of the 68Ga species, HPLC peaks, that may have formed during 
the chelation experiments, free 68GaCl3 (as eluted from generator with 0.1M HCl), 
68Ga-
hydrolyzed products, 68Ga-DTPA and 68Ga-Transferrin (Tf) were prepared as described25-
26,13 and their retention times were recorded on radio-HPLC. 
 
Stability (in vitro), transchelation and transmetallation studies 
 
For the stability, transchelation and transmetallation studies, 68Ga-peptide-chelators were 
prepared by mixing 300 µL (14.5 – 18.5 MBq) of 68GaCl3 in 0.1 M HCl, 120 µL of 1.0 M 
sodium acetate and 5 µL (20 µg) of peptide-chelators. The preparation was incubated at 
90°C for 30 min. Aliquots of 68Ga-peptide-chelators solutions (0.3 mL, approx. 15 MBq) 
were alternatively mixed with (1) 0.3 mL of a 0.9% NaCl, (2) 0.3 mL of a 100 nM 
Fe3+/Zn2+/Ca2+(for transmetallation study), (3) 0.3 mL of a 200 μM DTPA solution, (4) 
0.3 mL of a 50 μM transferrin solution (for transchelation study) and (5) 0.3 mL of 
human serum solution. The mixtures were incubated at 37 °C and analyzed after 0, 10, 
30, 60 and 120 min of incubation, respectively. A 10 μl (in 100µL of normal saline) 
aliquot preparations of  (1), (2) and (3) were injected in the radio-HPLC while 
preparations (4, 5) were analyzed by ITLC-SG using 0.1M citric acid as a solvent.  
 Cell binding (in vitro) assay  
 
Estrogen receptor-positive T47D human breast tumor cells from American Type Culture 
Collection were maintained in RPMI 1640 medium with 2 mM L-glutamine contained 10 
mM HEPES, 1.0 mM sodium pyruvate, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 
supplemented with 0.2 Units/ml 90 %bovine insulin, and 10% fetal bovine serum, at 
37°C under 5% CO2/95% air. The cells when confluent were detached using 0.25% 
trypsin-EDTA, washed and resuspended with RPMI-1640 medium at a concentration of ~ 
5× 106 cells/mL.  Each test tube contained 1 mL of cell suspension into which 10 µL of 
68Ga-peptide-chelator (approx. 0.74 MBq) was added and incubated for 2 hr at 37°C in a 
water bath. The incubation was terminated by adding 0.5 ml of cold normal saline. The 
mixture was centrifuged at 3000 rpm for 10 minutes. The supernatant from each wash 
was collected into marked test tubes. To the remaining pellet, 1.0 ml of normal saline was 
added and centrifuged again at 3000 rpm for 10 minutes. The supernatant was separated 
and collected in the marked test tube. The cells and supernatant were counted for 
radioactivity in a gamma counter and percentage of radioactivity bound on the cells was 
calculated.  
 
Biodistribution studies  
 
The biodistribution of 68Ga labeled peptide was studied in normal (n = 10, athymic nude, 
female mice, 20-25 g). The resultant optimal preparation procedure was used which 
contained 300 µL of  68GaCl3 in  0.1 N HCl, 120 µL of 1.0 M sodium acetate solution  
and 20 µg of  peptide conjugate, incubated for 10 min at RT (for NODAGA-peptide) and 
90ºC (for DOTA-peptide). Following determination of radiochemical purity (> 95%) by 
radio-HPLC analysis, 68Ga-peptide (3.7 – 5.5 MBq) was administered intravenously 
through a lateral tail vein in 200 µL of the preparation (pH ≈ 5.5). Radioactivity in the 
syringe before and after administration was measured in an energy-calibrated dose 
calibrator (CRC-15; Capintec, Ramssey, NJ), and the exact quantity received by each 
animal was determined. A standard 68GaCl3 solution of a known quantity was prepared at 
the time of injection. The animals (n = 5, each study) were sacrificed at 1 h post injection 
by CO2 inhalation. Various organs were removed, washed free of blood, blotted dry, and 
weighed. The associated radioactivity was counted in the γ-counter and results were 
calculated as percentage injected dose per gram (% ID/g) of tissue.  
 
 
 
 
 
Results  
 
Purity of peptide-chelators conjugates 
 
NODAGA- and DOTA-peptide purity as determined by HPLC was 99%. The MALDI-
TOF demonstrated that, for NODAGA-peptide observed molecular mass was 3716 
(calculated molecular mass-3718) whereas for DOTA-peptide observed molecular weight 
was 3787 (calculated molecular mass-3785). The MALDI peaks for the peptide 
conjugates are given in Figure 1A and B. 
 
Radiolabeling kinetics 
 
Optimal radiolabeling (> 95.0%) of the DOTA-conjugated peptide required pH 2-5 and 
higher (50-90ºC) temperature, while the NODAGA conjugated peptide needed incubation 
only at room temperature at same pH range. At higher temperature (90°C), the 
radiolabeling was not affected by pH for both peptide conjugates (Fig. 2A, B) and can be 
labeled at wide range of pH (1.0 – 6.0).  NODAGA-peptide can bind 68Ga at a minimal 
quantity of 1 µg but DOTA-peptide required minimum of 20 µg to yield optimal (≥ 95%) 
radiolabeling (Fig. 2C). The minimum incubation time needed for optimal (> 95%) 
radiolabeling was 10 minutes at 90°C (Fig. 2D). Radio-HPLC showed retention time for 
both radio-complexes was 9.9 ± 0.3 minutes as compared to 3.1 ± 0.2 minutes for free 
68Ga as shown in Fig. 3-b. The retention time was also determined for the reference 
standard like hydrolyzed  68GaCl3,
 68Ga-DTPA and 68Ga-transferrin and found to be 3.5 ± 
0.2 minutes.  
 
Stability studies 
 
Both 68Ga labeled peptide conjugates were stable in 0.9% normal saline (Fig. 4A) and 
showed minimal (1-2%) degradation against (FeCl3, CaCl2 and ZnCl2) transmetallation 
(Fig. 4B-D) up to 2 hours.  The transchelation study with DTPA (Fig. 5A) and transferrin 
(Fig. 5B) solution showed that both radio-complexes were remained intact over 2 hours. 
Radio-TLC showed ratio factor (Rf) value of 0.0-0.1 for 68Ga labeled peptide and 0.9-1.0 
for free 68GaCl3.. 
 
 
Cell binding (in vitro) assay  
 
Cell binding assay showed higher uptake for 68Ga-NODAGA-peptide, 34.0% ± 0.8% as 
compared with 24.5% ± 0.9% for 68Ga-DOTA-peptide at 15 minutes. However, at 2 
hours of incubation at 37ºC, the uptake was nearly same, 48.9% ± 3.9% for 68Ga-
NODAGA-peptide and 45.2% ± 2.1% for 68Ga-DOTA-peptide (Table – I).  
 
Biodistribution studies 
 
The biodistribution pattern of the both68Ga labeled peptide conjugate is shown in Figure 
6. In both cases, a higher uptake is seen in kidneys followed by liver, blood and lungs. It 
was evident that the 68Ga-NODAGA-Peptide showed rapid blood clearance as compared 
to 68Ga-DOTA-peptide. Liver uptake was 8.8% for 68Ga-NODAGA-Peptide was lower (p 
= 0.01) as compared to 16.5% for 68Ga-DOTA-peptide. Most of the activity was excreted 
through kidney. 
 
Discussion  
 
With its several advantages such as the availability in a generator form, cyclotron 
independency, multi elution ability in a single day, simplified radiolabeling chemistry 
with several biomolecules using bifunctional chelating agents, the use of 68GaCl3 is 
rapidly growing for diversified clinical applications.27 The presence of even µg levels of 
metallic impurities (with ageing of generator) in 68GaCl3 or reagent used may hamper the 
radiolabeling complexation. The removal of radionuclide impurities however has helped 
expansion of its use for clinical application.28 
 
The eluate of 68GaCl3 from the generator may contain metal ion impurities such as Fe
3+, 
Cu2+, Al3+, Zn2+ and Sn4+ which could hamper the radiolabeling of biomolecules. It is 
important therefore to identify the suitable chelating agent for the radiolabeling which is 
least affected by these impurities as well the stability of the labeled compound.29-30 
DOTA is the most commonly used chelating agent and 68Ga-DOTATOC is accepted in 
the European Pharmacopeia.31 68Ga labeled DOTA biomolecules conjugates (like 
peptides, antibody, and small molecules) have been successfully developed and used for 
many clinical applications. The disadvantage of DOTA conjugate is its slow reaction 
kinetics for complex formation with 68Ga.32 These limitations prompted us to investigate 
the use of NODAGA for comparison with DOTA. 
 
Chelator-peptide conjugates were synthesized by solid phase peptide synthesis method. 
Both peptide conjugates were synthesized with high purity (~ 99.0%). NODAGA- 
peptide conjugate showed faster kinetics as compare to DOTA- peptide conjugate and 
less influenced by the pH variation. NODAGA peptide conjugate yielded higher 
radiolabeling efficiency at minimal quantity of peptide (1 µg), at room temperature and 
within short incubation (5 min) time. For the preparations with short lived radionuclides 
like 68Ga, these characteristics of NODAGA are advantageous. The faster radiolabeling 
kinetics may be attributable to its ionic size compatibility with cavity size of the nine 
membered triazomacrocycle of NODAGA and therefore, yielding a high radiolabeling in 
5 min at room temperature.33 A low radiolabeling was observed in acidic (pH-1.0) 
conditions for both peptide conjugates when incubated at temperature (25-70°C). It may 
attribute to strongly acidic environment which might have protonated the donor atoms of 
the ligand and destabilized the 68Ga complex.34 At high temperature (~ 90°C), the 
radiolabeling was found to be independent of pH variation (Fig. 2 a-b). However at pH 7.0 
and above, labeling decreases (data not included). This may be due to a fact that at acidic pH, 
68Ga remains predominant in cation Ga3+ form (> 90%), though soluble complex ions Ga(OH)2+, 
Ga(OH)+2 may be  present in the solution. As the pH of the solution shifts towards basic (> 7.0), 
the hydrolyzed form of Gallium, Ga(OH)-4 increases and decreases the radiolabeling yield.35 Once 
the peptide conjugate is radiolabeled, then adjusting the pH to physiological pH 7.0 does not 
adversely influence the chelated Ga-68. 
 
The use of sodium acetate buffer maintained the pH and allowed strong formation BFC- 
68Ga complex. The other advantage of using sodium acetate buffer is its biocompatibility 
for human use.36 DOTA peptide conjugate showed labeling at high temperature.  
Therefore, DOTA may not be useful for those peptides which can denature at higher 
temperature and become unsuitable for molecular imaging. On the other hand, 
radiolabeling of NODAGA-peptide at room temperature ruled out major thermal 
denaturation. Radio-HPLC showed that the formation of the 68Ga-NODAGA and DOTA 
peptide conjugate has retention time of around 9.9 min whereas free 68Ga eluted at 3.6 
min (Fig. 3-b) and complex formation between 68Ga and NODAGA-peptide conjugate is 
shown in Fig. 3-a . HPLC UV detector also detected the UV peak for NODAGA and 
DOTA peptide conjugate at around 9.9 min. Therefore, it confirmed the complexation of 
the 68Ga with peptide conjugate which leads to the retention of the 68Ga labeled peptide 
approximately at the same time. 
 
Both radio-complexes were found to be stable in normal saline (Fig. 4a) and human 
serum over 120 minute. The stability in human serum (at 37°C) indicated its suitability 
for in vivo applications and showed their inertness towards the metal ion/species that may 
be present in the serum. The transmetallation study was important not because these ions 
are present as impurities in the eluate but these ions are also present in serum in 
appreciable quantity.37 68Ga-NODAGA and DOTA peptide conjugates showed minimal 
(1-2%) degradation in radiolabeling after 120 minute incubation with respective ion 
solution at 37°C (Fig. 4-b-d). This could also provide an indication about the stability of 
these radio-complexes in in vivo environment. Transferrin is the major protein in the 
plasma which is known to form a strong complex with 67Ga-citrate.38  The minimal 
transchelation (~1-2%) of 68Ga-peptide conjugates with transferrin showed the stability of 
radio-complexation (Fig. 5-a-b). 
 
The cell binding assay was performed on T47D breast cancer lines which express VPAC-
1 receptors on their surface.19 68Ga-NODAGA-peptide showed higher uptake in 15 
minute as compared to 68Ga-DOTA-peptide but the uptake was almost same at 2hr 
(Table-1) which may be due to saturation of the receptor site.  The biodistribution data 
(Fig. 6) showed that both radio-complexes were cleared through kidneys. Hence, renal 
system was the major route of clearance from the body. 68Ga-NODAGA-peptide was 
cleared rapidly form the blood and had significantly less liver uptake (p < 0.05) as 
compare to 68Ga-DOTA-peptide at 1 hr. The fast clearance from the blood may be 
advantageous in reducing the background radioactivity for PET imaging but it could also 
limit the accumulation of radioactivity at target (tumor) area. Hence, a detailed in vivo 
investigation will be required further for any conclusion.   
 
In the present study, we have showed that 68Ga-NODAGA-peptide exhibited most 
favorable features from radiochemistry point of view. Chelator NODAGA has flexibility 
over the influence of temperature and acidic environment.13 Labeling at room temperature 
provides an advantage and could prevent any deleterious effect on peptide conjugate due 
to heating. Both peptide conjugates were found to be stable in serum, against 
transchelation and transmetallation experimentations. A detailed in vivo study is in 
progress to investigate the influence of chelators on the biodistribution and tumor 
targeting.   
 
Conclusions 
 
A comparison between NODAGA and DOTA revealed that NODAGA-peptide conjugate 
could be efficiently radiolabeled with 68Ga at room temperature with high yield. 68Ga-
NODAGA-peptide conjugate remained stable in serum, in presence of major metal ions 
impurities, against transchelation with DTPA or transferrin. The biodistribution data 
showed its clearance from kidneys, which minimize the radiation burden on the organs. 
The clearance of 68Ga-NODAGA-peptide from blood was faster as compare to 68Ga-
DOTA-peptide and would be advantageous for PET imaging.  
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